Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 1, 2006, Pages 47-54

  Sipahi, Tansu ^a,c   Pocan, Hatice ^b   Akar, Nejat ^b  

^a FATIH UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Genetic polymorphisms; Sepsis; Severe sepsis

Indexed keywords

BLOOD CLOTTING FACTOR 5; CATHEPSIN G; CD14 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LYMPHOTOXIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEPSIS;

ADOLESCENT; ANTIGENS, CD; CATHEPSINS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGY, MOLECULAR; FACTOR V; FEMALE; GENOTYPE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INTERLEUKIN-6; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; SEPSIS; SERINE ENDOPEPTIDASES; SURVIVORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32344451648     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200108     Document Type: Article

References (40)

1. Stormorken A, Powell KR. Sepsis and shock. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics, 17th ed. Philadelphia: WB Saunders, 2004:846.
2. From the Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. JAMA 1990;263:937.
3. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock; role in prognosis and potential for therapy. Chest 2003;124:1103.
4. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296:298.
5. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699.
6. Kumar A, Short J, Parrillo JE. Genetic factors in septic shock. JAMA 1999;282:579.
7. Tabrizi AR, Zehnbauer BA, Freeman BD, Buchman TG. Genetic markers in sepsis. J Am Coll Surg 2001;192:106.
8. Emonts M, Hazelzet JA, de Groot R, Hermans PWM. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003;3:565.
9. Lin MT, Albertson TE. Genomic polymorphisms in sepsis. Crit Care Med 2004;32(2):569.
10. Esmon CT. The protein C pathway. Chest 2003;124:26s.
11. Simmonds RE, Lane DA. The endothelial cell protein C receptor: A candidate genetic risk factor for thrombosis. Thromb Haemost 2001;86:939.
12. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004;47:305.
13. Akar N, Gökdemir R, Özel D, Akar E. Endothelial cell protein C receptor (EPCR) gene exon III, 23bp insertion mutation in the Turkish pediatric thrombotic patients. Thromb Haemost 2002;88:1068.
14. Sambrano GR, Huang W, Farugi T, et al. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000;275:6819.
15. Herrmann SM, Funke-Kaiser H, Schmidt-Petersen K, et al. Characterization of polymorphic structure of cathepsin G Gene role in cardiovascular and cerebrovascular diseases. Arterioscler Thromb Vasc Biol 2001;21:1538.
16. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481.
17. Brown K, Luddington R, Baglin T. A common polymorphism in the tumor necrosis factor-alpha gene associated with high TNF levels is not a risk factor for venous thrombo-embolism. Br J Haematol 1998;101:480.
18. Akar N, Hasipek M. Tumor Necrosis Factor-alpha gene polymorphism (-308 G-A) in Turkish Pediatric Thrombosis Patients. Turk J Haematol 2002;19:39.
19. Klein W, Tromm A, Griga T, et al. The polymorphism at position -174 of the IL-6 gene is not associated with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2001;13:45.
20. Margaglione M, Grandone E, Capucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997;77:605.
21. Yilmaz E, Akar E, Akar N. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thromboembolic patients with and without prothrombin 20210 G-A. Turk J Haematol 2004;21(2):83.
22. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the Factor V Arg 506-Gln mutation. Blood Coagul Fibrinolysis 1995;6:245.
23. Akar N. Site specific mutagenesis: Usage for the mutation detection in thrombosis. Turk J Haematol 1998;15(3): 123.
24. REF Simmonds RE, Lane DA. Structural and functional implications of the intron/exon organisation of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: Comparison with the structure of CD1/major histocompatibility complex α 1 and α 2 domains. Blood 1999;94:632.
25. Ludecke B, Poller W, Olek K, Bartholome K. Sequence variant of the human cathepsin G gene. Hum Genet 1993; 91:83.
26. Sorensen TI, Nielsen GG, Andersen PK, et al. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727.
27. Shu Q, Fang X, Chen Q, Stuber F. IL-10 polymorphism is associated with increased incidence of severe sepsis. Chin Med J (Engl) 2003;116(11):1756.
28. Reid CL, Perrey C, Pravica V, et al. Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 2002;30:2216.
29. Stassen NA, Breit CM, Norfleet LA, Polk HC. IL-18 promoter polymorphisms correlate with the development of post-injury sepsis. Surgery 2003;134:351.
30. Garred P, Strøm JJ, Quist L, et al. Association of mannose-binding lectin polymorphisms with systemic inflammatory response syndrome. J Infect Dis 2003;188:1394.
31. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522.
32. Texereau J, Pene F, Chiche JD, et al. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004;32(5):5313.
33. Mira JP, Cariou A, Grall F, et al. Association of TNF 2, a TNF-α promotor polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561.
34. Feeman BD, Buchman TG. Gene in a haystack: Tumor necrosis factor polymorphisms and outcome in sepsis. Crit Care Med 2000;28:3090.
35. Tang GJ, Huang SL, Yien HW, et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000;28:2733.
36. Schlüter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002;30(1): 32.
37. Ahrens P, Kattner E, Kohler B, et al. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res 2004;55(4):652.
38. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999;354:556.
39. Haralambous E, Hibberd ML, Hermans PW, et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003;31(12):2788.
40. Saposnik B, Reny JL, Gaussem P, et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004;103(4):1311.